PFE

Pfizer
D

PFE

Arincen59/100B
29.390
USD
-0.49
(-1.64%)
Post Trading·29.320USD-0.070(-0.24%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.72Revenue estimate 17.14B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Pfizer revenue 1985–2026

Pfizer's revenue in Q3 FY2026, the three months to 27 September 2026, was 16.58B USD, down 0.4% on the same quarter a year before. Pfizer's revenue over the last twelve months was 63.62B USD, up 1.3% on the twelve months before. In fiscal year 2025 it was 62.58B USD, down 1.6% on the year before.

Last updated 3 Nov 2026 · Next report 2 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM27 Sept 202663.62B+1.33%46.68B4.03B
FY202531 Dec 202562.58B-1.65%46.51B7.77B
FY202431 Dec 202463.63B+6.84%45.78B8.03B
FY202331 Dec 202359.55B-41.14%34.60B2.12B
FY202231 Dec 2022101.18B+24.46%66.83B31.37B
FY202131 Dec 202181.29B+95.16%50.47B21.98B
FY202031 Dec 202041.65B+1.82%33.17B9.16B
FY201931 Dec 201940.91B+0.20%32.85B16.03B
FY201831 Dec 201840.83B-22.31%31.84B11.15B
FY201731 Dec 201752.55B-0.53%41.32B21.31B
FY201631 Dec 201652.82B+8.13%40.50B7.22B
FY201531 Dec 201548.85B-1.52%39.20B6.96B
FY201431 Dec 201449.61B-3.84%40.03B9.14B
FY201331 Dec 201351.58B-5.62%42.00B22.00B
FY201231 Dec 201254.66B-10.45%44.84B14.57B
FY201131 Dec 201161.04B-6.34%48.54B10.01B
FY201031 Dec 201065.17B+30.31%50.38B8.26B
FY200931 Dec 200950.01B+3.55%41.12B8.64B
FY200831 Dec 200848.30B-0.25%40.18B8.10B
FY200731 Dec 200748.42B+0.10%37.18B8.14B
FY200631 Dec 200648.37B+2.04%40.73B19.34B
FY200531 Dec 200547.41B-3.23%40.17B8.09B
FY200431 Dec 200448.99B+9.50%42.60B11.36B
FY200331 Dec 200344.74B+38.53%35.15B3.91B
FY200231 Dec 200232.29B+11.27%28.28B9.13B
FY200131 Dec 200129.02B-1.13%25.20B7.79B
FY200031 Dec 200029.36B+7.23%24.35B3.73B
FY199931 Dec 199927.38B+17.84%22.71B4.95B
FY199831 Dec 199823.23B+110.14%19.02B4.63B
FY199731 Dec 199711.06B+12.07%9.71B2.21B
FY199631 Dec 19969.86B-1.57%8.53B1.93B
FY199531 Dec 199510.02B+21.01%8.23B1.57B
FY199431 Dec 19948.28B+10.75%6.65B1.30B
FY199331 Dec 19937.48B+3.42%5.96B657.50M
FY199231 Dec 19927.23B+4.03%5.47B810.90M
FY199131 Dec 19916.95B+8.49%4.99B722.10M
FY199031 Dec 19906.41B+12.95%4.37B801.20M
FY198931 Dec 19895.67B+5.31%3.82B681.10M
FY198831 Dec 19885.39B+9.46%3.56B791.30M
FY198731 Dec 19874.92B+9.92%3.18B690.20M
FY198631 Dec 19864.48B+11.22%2.90B660.00M
FY198531 Dec 19854.02B—2.61B579.70M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Pfizer revenue growth by segment

Q3 FY2026 against Q3 FY2025

Biopharma16.28B
-0.2%
Segment Reporting, Reconciling Item, Corporate Nonsegment300.00M
-12.8%

Pfizer revenue by segment over time

Biopharma Segment Reporting, Reconciling Item, Corporate Nonsegment Global Innovative Pharmaceutical Global Established Pharmaceutical Global Vaccines, Oncology and Consumer Healthcare Essential Health Innovative Health Upjohn Business Innovation
Fiscal yearBiopharmaSegment Reporting, Reconciling Item, Corporate NonsegmentGlobal Innovative PharmaceuticalGlobal Established PharmaceuticalGlobal Vaccines, Oncology and Consumer HealthcareEssential HealthInnovative HealthUpjohnBusiness Innovation
FY202561.20B -1.9%1.38B — — — — — — —
FY202462.40B +9.1%— — — — — — — —
FY202357.19B -42.2%— — — — — — — 1.31B
FY202298.99B +24.4%— — — — — — — —
FY202179.56B — — — — — — — —
FY201939.42B — — — — — — 10.23B —
FY2018— — — — — 20.22B -4.3%33.43B +6.4%— —
FY2017— — — — — 21.12B -10.6%31.42B +7.6%— —
FY2016— — — — — 23.63B 29.20B — —
FY2015— — 13.95B +0.7%21.59B -14.2%12.80B +26.2%— — — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Pfizer's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.